

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 63537

**Title:** Discontinuation of antiviral therapy in chronic hepatitis B patients

**Reviewer's code:** 02441021

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Professor

**Reviewer's Country/Territory:** Egypt

**Author's Country/Territory:** Portugal

**Manuscript submission date:** 2021-01-29

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-04-11 18:49

**Reviewer performed review:** 2021-04-13 22:03

**Review time:** 2 Days and 3 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

#### **SPECIFIC COMMENTS TO AUTHORS**

Lots of English language and grammar mistakes that have to be corrected by a native English speaking person. • Current recommendations on finite NUC therapy APASL.....Explain what it stands for.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 63537

**Title:** Discontinuation of antiviral therapy in chronic hepatitis B patients

**Reviewer's code:** 05427992

**Position:** Peer Reviewer

**Academic degree:** FAASLD, AGAF, MD

**Professional title:** Professor

**Reviewer's Country/Territory:** Thailand

**Author's Country/Territory:** Portugal

**Manuscript submission date:** 2021-01-29

**Reviewer chosen by:** Ya-Juan Ma

**Reviewer accepted review:** 2021-04-20 06:11

**Reviewer performed review:** 2021-04-20 06:43

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

I have read "Discontinuation of antiviral therapy in chronic hepatitis B patients" with interest. There are some comments and suggestions 1. HBeAg seroconversion in non-cirrhotic is just one possible end-point but most guideline recommend until HBsAg loss. 2. Publication cited for HBsAg loss was included small sample size, the authors did not include publication that include larger, more recent 3. Type of NUC or any predictors of relapse? 4. Recommendation of stopping NUC, even may offer some benefit but to recommend for general practice may be too early. NUC stopping should be reserved for HBeAg negative patients without baseline advanced fibrosis and in highly motivated patients who can be followed more frequently

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 63537

**Title:** Discontinuation of antiviral therapy in chronic hepatitis B patients

**Reviewer's code:** 05424290

**Position:** Peer Reviewer

**Academic degree:** MBBS, MD

**Professional title:** Academic Research, Doctor, Professor

**Reviewer's Country/Territory:** India

**Author's Country/Territory:** Portugal

**Manuscript submission date:** 2021-01-29

**Reviewer chosen by:** Ya-Juan Ma

**Reviewer accepted review:** 2021-04-23 07:59

**Reviewer performed review:** 2021-05-01 11:18

**Review time:** 8 Days and 3 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

#### **SPECIFIC COMMENTS TO AUTHORS**

Dear Authors I wish to congratulate you on an extensive and near complete review of this important topic. We all practice CHB in our clinical practice and you have rightly elaborated all the possible ways for discontinuation of therapy.. There are few comments I wish to make. 1. Minor grammatical mistakes can be checked and corrected. 2. correction of "HBAg" in text as "HBsAg" is needed at certain places. 3. You can also include brief description regarding "Host dominating flare" and "Virus dominating flare". Rest all is good.